Alvotech

72 articles with Alvotech

• Alvotech to Present Switching Study Data for AVT02, a Proposed Biosimilar to Humira®, at 2022 American College of Rheumatology Conference

  11/10/2022

  Alvotech announced that it will present two posters and will be featured in an Ignite Talk related to its switching study for ATV02 at the American College of Rheumatology Convergence Conference, being held in Philadelphia on November 10-14, 2022.

• Alvotech to Report First Nine Months Financial Results on November 15, 2022 and Host Business Update Conference Call at 8:00 am ET on November 16, 2022

  10/27/2022

  Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first nine months of 2022, after U.S. markets close on Tuesday, November 15, 2022.

• Alvotech to Participate in Upcoming Jefferies London Healthcare Conference in November

  10/26/2022

  Alvotech (NASDAQ: ALVO), a global biotech specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that members of the leadership team will participate in the Jefferies London Healthcare Conference from November 15th to November 17th.

• Alvotech and JAMP Pharma Expand Exclusive Partnership Adding Two Biosimilar Candidates for Canadian Market, Bringing New Options for Patients in Specialty Care

  10/19/2022

  Alvotech and the JAMP Pharma Group announced that the companies have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech, by adding two biosimilar candidates from Alvotech’s pipeline: AVT16 a biosimilar for an immunology product and AVT33, a biosimilar for an oncology product.

• Alvotech’s Partner Submits Application for Marketing Approval of First Biosimilar Candidate in Japan

  10/17/2022

  Alvotech announced that its commercialization partner Fuji Pharma Co., Ltd. has submitted an application to the Japanese Ministry of Health, Labor and Welfare for marketing approval of the first biosimilar candidate developed under the companies’ exclusive commercialization partnership.

• Alvotech Appoints Sarah Tanksley as Chief Quality Officer

  10/11/2022

  Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Sarah Tanksley will join its corporate leadership team as Chief Quality Officer, effective October 14.

• Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®

  9/22/2022

  Alvotech (NASDAQ: ALVO) and STADA Arzneimittel AG (STADA), announced today the launch of Hukyndra®, a high-concentration, low-volume, citrate-free formulation, biosimilar to Humira® (adalimumab), in Switzerland.

• Alvotech Reports Update on Initial AVT02 Biologics License Application

  9/5/2022

  Alvotech announced that Alvotech received communication from the U.S. Food and Drug Administration detailing its assessment of the March 2022 inspection of Alvotech’s manufacturing facility in Reykjavik, Iceland and Alvotech’s subsequent written responses to the FDA.

• Alvotech Reports First Half 2022 Financial Results and Business Update

  8/31/2022

  Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for the first half of 2022 and provided a summary of recent corporate highlights.

• Alvotech Announces Corporate Sustainability Participation and Discloses ESG Data covering 2020 and 2021

  8/29/2022

  Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced that the Company has released data on environmental, social and governance indicators for 2020 and 2021, to provide further transparency to stakeholders.

• Alvotech Initiates Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

  8/25/2022

  Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced the initiation of a confirmatory patient study for AVT03, a biosimilar candidate to Prolia® and Xgeva®.

• Alvotech to Participate in Two Upcoming Investor Conferences in September 2022

  8/24/2022

  Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced that members of the leadership team will participate in two upcoming investor conferences in September 2022.

• Alvotech to Report First Six Months and Second Quarter 2022 Financial Results on August 31, 2022 and Host Business Update Conference Call at 8:00 am ET on September 1, 2022

  8/15/2022

  Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced that it will release financial results for the first six months and second quarter of 2022, after U.S. markets close on Wednesday, August 31, 2022.

• Alvotech’s Board of Directors Approves Plan to Prepare for Listing on Nasdaq Main Market in Iceland

  8/12/2022

  Alvotech announced that its Board of Directors has approved a plan to move its share listing from the First North Growth Market to the Nasdaq Main Market in Iceland.

• Alvotech Initiates a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

  7/20/2022

  Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic study for AVT03 (denosumab), a biosimilar candidate to Prolia® and Xgeva®.

• Alvotech Expands its Board of Directors as part of Transition from Private to Publicly Traded Company

  7/14/2022

  Alvotech, a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced the expansion of its board of directors as part of its transition from a private to a publicly traded company.

• Alvotech Initiates Patient Study for AVT06, a Proposed Biosimilar for Eylea®

  7/7/2022

  Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of the company’s confirmatory clinical study for AVT06 (aflibercept), a biosimilar candidate to Eylea®.

• Alvotech, a Global Pureplay Biosimilars Company, to Debut on Nasdaq Under the Ticker ALVO on June 16

  6/15/2022

  Alvotech, a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide announced that its ordinary shares and warrants will begin trading on the Nasdaq Stock Market LLC on Thursday, June 16, under the new ticker symbols “ALVO” and “ALVOW”, respectively.

• STADA and Alvotech broaden European patients’ options by launching Hukyndra® high-concentration, citrate-free adalimumab

  6/9/2022

  STADA and Alvotech broaden European patients’ options by launching Hukyndra ® high-concentration, citrate-free adalimumab.

• Alvotech and Oaktree Acquisition Corp. II Announce Shareholder Approval of Business Combination

  6/7/2022

  Alvotech Holdings S.A. and Oaktree Acquisition Corp. II announced that their previously announced business combination between Alvotech S.A., OACB and the legal entity named Alvotech, previously named Alvotech Lux Holdings S.A.S., with Alvotech as the surviving entity was approved by OACB shareholders at an Extraordinary General Meeting on June 7, 2022.